Coffee for non-alcoholic fatty liver disease
- Conditions
- on-alcoholic fatty liver disease (NAFLD)Non-alcoholic fatty liver disease (NAFLD)Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
- Registration Number
- ACTRN12621001210864
- Lead Sponsor
- Austin Health
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 150
Patients with a diagnosis of NAFLD with evidence of hepatic steatosis on liver ultrasound and/or Fibroscan CAP score of >260 dB/m and abnormal liver function tests.
Patients who are non-coffee drinkers or irregular coffee drinkers.
1. Patients who regularly consume coffee
2. Patients with causes of liver disease other than NAFLD
3. Alcohol intake greater than 1 (female) or 2 (male) standard drinks per day
4. Patients with poorly controlled diabetes (i.e. HbA1c >9.5%)
5. Patients with diabetes who have had a recent change in diabetic treatment regimen within the last 3 months
6. Patients who have been involved in a NAFLD trial within the last 3 months
7. Patients with decompensated liver cirrhosis
8. Patients who have recently been on antibiotics within the last 3 months
9. Patients who are on medications known to potentially cause fatty liver
10. Patients with significant change in weight (>5%) within the last 3 months
11. Patients who have contraindications to MRI scanning or unable to have MRI scan for any other reason
12. Patients unable to consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage change in hepatic steatosis as quantified by magnetic resonance imaging proton density fat fraction (MRI-PDFF)[Baseline and 26 weeks after enrolment]
- Secondary Outcome Measures
Name Time Method